No headlines found.
Globe Newswire (Thu, 28-Mar 8:05 AM ET)
Agile Therapeutics Announces Delisting from Nasdaq
Globe Newswire (Mon, 25-Mar 4:30 PM ET)
Globe Newswire (Thu, 21-Mar 6:35 AM ET)
Globe Newswire (Wed, 20-Mar 8:15 AM ET)
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
Globe Newswire (Wed, 13-Mar 7:31 AM ET)
Globe Newswire (Tue, 12-Mar 10:20 AM ET)
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
Globe Newswire (Thu, 22-Feb 9:01 AM ET)
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Agile Therapeutics trades on the stock market under the symbol AGRX.
As of April 25, 2024, AGRX stock price was flat at $0.60 with million shares trading.
AGRX has a beta of 1.12, meaning it tends to be more sensitive to market movements. AGRX has a correlation of 0.02 to the broad based SPY ETF.
AGRX has a market cap of $1.51 million. This is considered a Sub-Micro Cap stock.
Last quarter Agile Therapeutics reported $4 million in Revenue and -$1.46 earnings per share. This fell short of revenue expectation by $-455,000 and missed earnings estimates by -$.54.
In the last 3 years, AGRX stock traded as high as $3,940.00 and as low as $.50.
AGRX has underperformed the market in the last year with a return of -90.9%, while the SPY ETF gained +23.2%. In the last 3 month period, AGRX fell short of the market, returning -62.1%, while SPY returned +3.6%. However, in the most recent 2 weeks AGRX has outperformed the stock market by returning 0.0%, while SPY returned -2.5%.
AGRX support price is $.59 and resistance is $.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGRX stock will trade within this expected range on the day.